These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Soluble urokinase plasminogen activator receptor: from biomarker to active participant in atherosclerosis and cardiovascular disease. Goodchild TT; Li Z; Lefer DJ J Clin Invest; 2022 Dec; 132(24):. PubMed ID: 36519539 [TBL] [Abstract][Full Text] [Related]
5. Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation. Rasmussen LJH; Petersen JEV; Eugen-Olsen J Front Immunol; 2021; 12():780641. PubMed ID: 34925360 [TBL] [Abstract][Full Text] [Related]
6. Soluble urokinase-type plasminogen activator receptor (suPAR) is elevated in caregivers of patients with parkinsonism. Joyce J; Cabanas N; Pisharody R; Ouyang B; Patel R; Reiser J; Hall DA; Witek N Parkinsonism Relat Disord; 2022 Aug; 101():39-42. PubMed ID: 35780693 [TBL] [Abstract][Full Text] [Related]
7. Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes. Rotbain Curovic V; Theilade S; Winther SA; Tofte N; Eugen-Olsen J; Persson F; Hansen TW; Jeppesen J; Rossing P Diabetes Care; 2019 Jun; 42(6):1112-1119. PubMed ID: 30885954 [TBL] [Abstract][Full Text] [Related]
8. Soluble Urokinase Plasminogen Activator Receptor Levels and Outcomes in Patients with Heart Failure. Hayek SS; Tahhan AS; Ko YA; Alkhoder A; Zheng S; Bhimani R; Hartsfield J; Kim J; Wilson P; Shaw L; Wei C; Reiser J; Quyyumi AA J Card Fail; 2023 Feb; 29(2):158-167. PubMed ID: 36122818 [TBL] [Abstract][Full Text] [Related]
9. Soluble Urokinase Plasminogen Activator Receptor: Genetic Variation and Cardiovascular Disease Risk in Black Adults. Olson NC; Raffield LM; Moxley AH; Miller-Fleming TW; Auer PL; Franceschini N; Ngo D; Thornton TA; Lange EM; Li Y; Nickerson DA; Zakai NA; Gerszten RE; Cox NJ; Correa A; Mohlke KL; Reiner AP Circ Genom Precis Med; 2021 Dec; 14(6):e003421. PubMed ID: 34706549 [TBL] [Abstract][Full Text] [Related]
11. Soluble Urokinase Plasminogen Activator Receptor is Associated with Coronary Artery Calcification and Cardiovascular Disease in Patients Undergoing Hemodialysis. Wu W; Cui Y; Hu J; Liao R; Li S; Mo L; Xu L; Chen Y; Lian Z; Tian X; Li Z; Li R; Zhang L; Liang H; Ma J; Lin T; Feng Z; Dong W; Ke G; Ge P; Ye Z; Wang W; Zhang B; Shi W; Liang X; Liu S Kidney Blood Press Res; 2018; 43(3):664-672. PubMed ID: 29734173 [TBL] [Abstract][Full Text] [Related]
12. Soluble urokinase plasminogen activator receptor is associated with inflammation in the vulnerable human atherosclerotic plaque. Edsfeldt A; Nitulescu M; Grufman H; Grönberg C; Persson A; Nilsson M; Persson M; Björkbacka H; Gonçalves I Stroke; 2012 Dec; 43(12):3305-12. PubMed ID: 23150653 [TBL] [Abstract][Full Text] [Related]
13. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study. Persson M; Engström G; Björkbacka H; Hedblad B Atherosclerosis; 2012 Feb; 220(2):502-5. PubMed ID: 22119508 [TBL] [Abstract][Full Text] [Related]
14. Cadmium exposure is associated with soluble urokinase plasminogen activator receptor, a circulating marker of inflammation and future cardiovascular disease. Fagerberg B; Borné Y; Barregard L; Sallsten G; Forsgard N; Hedblad B; Persson M; Engström G Environ Res; 2017 Jan; 152():185-191. PubMed ID: 27792942 [TBL] [Abstract][Full Text] [Related]